Truist Securities expressed a positive outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $120 from $110, while reaffirming a Buy rating. The stock, currently trading near its ...

Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment ...

Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...

Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific (BSX) to $120 from $110 and keeps a Buy rating on the ...

The company primarily operates through its MedSurg (endoscopy, urology, and neuromodulation ... a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp ...

I had high expectations for Boston Scientific going into 2024 – at ... and other less-celebrated businesses like urology and peripheral vascular continue to perform well. As far as dangers ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Boston Scientific Corp. engages in the development ... The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral ...